# DESCRIPTION

- claim priority to provisional patent application

## TECHNICAL FIELD

- define technical fields of disclosure

## BACKGROUND

- introduce radiofrequency therapy for cancer
- discuss prior art and limitations

## BRIEF SUMMARY

- introduce non-invasive radiofrequency therapy for cancer
- describe therapy with cancer drugs
- discuss synergism between radiofrequency and cancer drugs
- describe reduced cancer drug amount
- discuss enhanced transport and perfusion
- exclude radiofrequency absorption enhancers
- describe physiological benefits
- discuss improved transport and uptake
- describe method of increasing perfusion
- discuss intra-tumoral blood vessel permeability
- describe interactions of high-frequency radiowaves
- discuss imaging of labeled compounds
- describe non-invasive radiofrequency therapy system
- discuss portable radiofrequency generator

## DETAILED DESCRIPTION

- define terms and conventions

### I. General Embodiments

- describe dielectric properties of cancerous and normal tissues
- introduce radiofrequency energy for cancer treatment
- explain radiofrequency therapy for chemoresistant cancer
- describe non-invasive radiowave-induced hyperthermia

### II. Radiofrequency Therapy Embodiments

- introduce non-invasive radiofrequency therapy for cancer treatment
- describe radiofrequency therapy system components
- explain transmission and reception head configuration
- describe energy absorption and temperature increase
- introduce frequency and power optimization
- describe temperature monitoring
- explain frequency range and duration of exposure
- describe multiple exposures and cancer drug delivery
- summarize non-invasive radiofrequency therapy

### III. Chemoresistant Cancer Drugs

- introduce cancer drugs and radiofrequency therapy combination
- describe cancer drugs and their mechanisms of action

### IV. Pharmaceutical Preparations of Cancer Drugs

- define pharmaceutical compositions
- describe pharmaceutically acceptable carriers
- list examples of carriers
- describe administration routes
- formulate composition with semi-solid or solid carrier
- add stabilizing agents
- describe pharmaceutical lipid vehicle compositions
- disperse cancer drug in lipid vehicle
- determine dosage amount
- describe factors affecting dosage
- provide examples of dosages
- describe alimentary compositions and formulations
- formulate for oral administration
- describe excipients and additives
- formulate for buccal, rectal, or sublingual administration
- describe parenteral compositions and formulations
- formulate for intravenous, intradermal, intramuscular, intraarterial, intrathecal, subcutaneous, or intraperitoneal
- describe solutions, dispersions, and powders for injectable use
- describe miscellaneous pharmaceutical compositions and formulations
- formulate for topical administration
- describe transdermal administration
- formulate for mucosal administration
- formulate for inhalation
- describe kits comprising the cancer drug

### V. Therapeutic Embodiments

- outline therapeutic treatment
- specify treatment details

## EXAMPLES

- provide preferred embodiments

### Example 1

- introduce nude mice model
- describe tumor establishment
- outline animal euthanization procedure
- introduce portable RF system
- describe p-RF system components
- illustrate p-RF experimental setup
- describe tumor temperature modulation experiment
- outline IVM-RF system setup
- describe RF-IVM animal manipulation
- introduce fluorescent markers
- describe immunofluorescent imaging
- outline algorithms for quantifying fluorescent tracer perfusion
- illustrate tumor temperature elevations
- discuss dielectric properties of tumors
- introduce equation for complex permittivity function
- define heating rate equation
- describe vessel degradation
- illustrate multi-channel IVM-RF imaging
- depict changes in vessel architecture
- show RF-induced fluorescent tracer transport
- illustrate perfusion of albumin tracer
- perform post RF analysis
- show prolonged RF-induced biological effects
- illustrate RF-enhanced perfusion in orthotopic Panc-1 pancreatic tumors
- show RF-enhanced uptake of chemotherapy drugs
- illustrate synergy between RF exposure and chemotherapeutics
- discuss significance of certain embodiments
- describe custom portable RF system
- summarize results and significance

### Example 2

- introduce primary hepatocellular carcinoma
- describe current treatment options
- motivate gemcitabine resistance
- summarize mechanisms of gemcitabine resistance
- introduce hyperthermia as a potential solution
- describe cell lines and reagents used
- detail cell culture and transfection methods
- describe western blot analysis
- introduce immunocytochemistry assay
- detail immunocytochemistry protocol
- describe confocal imaging
- introduce immunohistochemistry
- detail immunohistochemistry protocol
- describe chromogen-based immunohistochemistry
- introduce clonogenic assays
- detail clonogenic assay protocol
- introduce cell cycle analysis
- detail BrdU-labeling protocol
- describe flow cytometry analysis
- introduce mouse model of hepatocellular carcinoma
- detail tumor implantation protocol
- describe bioluminescence imaging
- describe animal model
- detail radiofrequency generator setup
- outline statistical analyses
- describe protein electrophoresis and immunoblotting
- detail thermal imaging and fiber optic thermography
- describe animal model of human HCC and RF-hyperthermia
- evaluate effect of hyperthermia on HRR-pathway proteins
- localize HRR-pathway proteins to gemcitabine-stalled replication forks
- describe cell cycle alterations
- detail clonogenic survival and viability
- evaluate effect of mirin on gemcitabine toxicity
- develop partial Mre11 knockdown cell line
- describe animal model studies
- detail tumor treatment and analysis
- evaluate effect of combination therapy on tumor mass
- repeat experiment in HepG2 xenograft model
- assess thermomimetic effect of mirin
- evaluate localization of Mre11 and Rad51
- analyze Î³-H2AX-positive cells in tumors
- summarize results

### Significance of Certain Embodiments

- implicate pathways in chemoresistance
- evaluate HRR-pathway proteins
- discuss thermal degradation of BRCA2
- explain synergistic interaction between hyperthermia and gemcitabine
- summarize thermal enhancement of anti-tumor effect

